title: Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease.
abstract: Caspase-3 is an effector of apoptosis in experimental models of Parkinson's disease (PD). However, its potential role in the human pathology remains to be demonstrated. Using caspase-3 immunohistochemistry on the postmortem human brain, we observed a positive correlation between the degree of neuronal loss in dopaminergic (DA) cell groups affected in the mesencephalon of PD patients and the percentage of caspase-3-positive neurons in these cell groups in control subjects and a significant decrease of caspase-3-positive pigmented neurons in the substantia nigra pars compacta of PD patients compared with controls that also could be observed in an animal model of PD. This suggests that neurons expressing caspase-3 are more sensitive to the pathological process than those that do not express the protein. In addition, using an antibody raised against activated caspase-3, the percentage of active caspase-3-positive neurons among DA neurons was significantly higher in PD patients than in controls. Finally, electron microscopy analysis in the human brain and in vitro data suggest that caspase-3 activation precedes and is not a consequence of apoptotic cell death in PD.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale U 289, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, 75013 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Hartmann
authors.forename: S
authors.initials: S
authors.lastname: Hunot
authors.forename: P P
authors.initials: PP
authors.lastname: Michel
authors.forename: M P
authors.initials: MP
authors.lastname: Muriel
authors.forename: S
authors.initials: S
authors.lastname: Vyas
authors.forename: B A
authors.initials: BA
authors.lastname: Faucheux
authors.forename: A
authors.initials: A
authors.lastname: Mouatt-Prigent
authors.forename: H
authors.initials: H
authors.lastname: Turmel
authors.forename: A
authors.initials: A
authors.lastname: Srinivasan
authors.forename: M
authors.initials: M
authors.lastname: Ruberg
authors.forename: G I
authors.initials: GI
authors.lastname: Evan
authors.forename: Y
authors.initials: Y
authors.lastname: Agid
authors.forename: E C
authors.initials: EC
authors.lastname: Hirsch
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D017209:Apoptosis; D015153:Blotting, Western; D001921:Brain / Q000201:enzymology* / Q000648:ultrastructure; D053148:Caspase 3; D020169:Caspases / Q000096:biosynthesis* / Q000502:physiology*; D002478:Cells, Cultured; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology; D004789:Enzyme Activation; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008636:Mesencephalon / Q000201:enzymology; D051379:Mice; D008810:Mice, Inbred C57BL; D009474:Neurons / Q000201:enzymology / Q000648:ultrastructure; D010300:Parkinson Disease / Q000201:enzymology* / Q000378:metabolism; D051381:Rats; D013378:Substantia Nigra / Q000201:enzymology; D014018:Tissue Distribution; D017557:Ventral Tegmental Area / Q000201:enzymology
chemical_list: D015259:Dopamine Agents; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; C505407:CASP3 protein, human; C505409:Casp3 protein, mouse; C505410:Casp3 protein, rat; D053148:Caspase 3; D020169:Caspases; D004298:Dopamine